Dupont Capital Management Corp Glycomimetics Inc Transaction History
Dupont Capital Management Corp
- $889 Million
- Q1 2025
Shares
2 transactions
Others Institutions Holding GLYC
# of Institutions
38Shares Held
30.8MCall Options Held
80.9KPut Options Held
20.8K-
Bvf Inc San Francisco, CA9.54MShares$2 Million0.09% of portfolio
-
Logos Global Management LP San Francisco, CA5.4MShares$1.13 Million0.22% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA5.09MShares$1.07 Million0.0% of portfolio
-
Vr Adviser, LLC New York, NY3MShares$630,0000.15% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.67MShares$560,7430.0% of portfolio
About GLYCOMIMETICS INC
- Ticker GLYC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 52,423,900
- Market Cap $11M
- Description
- GlycoMimetics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. It is developing uproleselan, an E-selectin inhibitor, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML),...